SWM
ACAD icon

SeaCrest Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

SeaCrest Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16,100
Closed -$334K – 2122
2018
Q3 		$334K Buy
+16,100
New +$253K 0.06% 365
2018
Q2 		– Sell
-500
Closed -$11K – 2186
2018
Q1 		$11K Sell
500
-700
-58% -$19.4K ﹤0.01% 1534
2017
Q4 		$36K Buy
+1,200
New +$38.4K 0.01% 1093

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SeaCrest Wealth Management's ACAD Position: Q4 2018 in Review

SeaCrest Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 16,100 shares — an estimated $334K sold.

SeaCrest Wealth Management first reported a position in ACAD in Q4 2017 and held it in 3 quarters. The position peaked at $334K in Q3 2018. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

  • SeaCrest Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 16,100 Acadia Pharmaceuticals shares in Q4 2018, an estimated $334K.
  • SeaCrest Wealth Management first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 3 quarters.
  • SeaCrest Wealth Management's Acadia Pharmaceuticals position peaked at $334K in Q3 2018.
  • 186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on SeaCrest Wealth Management's 13F filing for Q4 2018, filed 13 Feb 2019.